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Abstract
Background: Pulmonary arterial hypertension (PAH) is a rare and progressive vascular disorder characterized by increased
pulmonary vascular resistance and right heart failure. The aim of this study was to analyze the Bone Morphogenetic Protein
Receptor 2 (BMPR2), Activin A type II receptor like kinase 1 (ALK1/ACVRL1) and potassium voltage-gated channel,
shakerrelated subfamily, member 5 (KCNA5) genes in patients with idiopathic and associated PAH. Correlation among
pathogenic mutations and clinical and functional parameters was further analyzed.
Methods and Results: Forty one patients and fifty controls were included in this study. Analysis of BMPR2, ACVRL1 and
KCNA5 genes was performed by polymerase chain reaction (PCR) and direct sequencing. Fifty one nucleotide changes were
detected in these genes in 40 of the 41 patients; only 22 of these changes, which were classified as pathogenic, have been
detected in 21 patients (51.2%). Ten patients (62.5%) with idiopathic PAH and 10 (40%) with associated PAH showed
pathogenic mutations in some of the three genes. Several clinical and hemodynamics parameters showed significant
differences between carriers and non-carriers of mutations, being more severe in carriers: mean pulmonary artery pressure
(p = 0.043), pulmonary vascular resistence (p = 0.043), cardiac index (p = 0.04) and 6 minute walking test (p = 0.02). This
differences remained unchanged after adjusting for PAH type (idiopathic vs non idiopathic).
Conclusions: Pathogenic mutations in BMPR2 gene are frequent in patients with idiopathic and associated PAH group I.
Mutations in ACVRL1 and KCNA5 are less frequent. The presence of these mutations seems to increase the severity of the
disease.
Citation: Pousada G, Baloira A, Vilariño C, Cifrian JM, Valverde D (2014) Novel Mutations in BMPR2, ACVRL1 and KCNA5 Genes and Hemodynamic Parameters in
Patients with Pulmonary Arterial Hypertension. PLoS ONE 9(6): e100261. doi:10.1371/journal.pone.0100261
Editor: Shama Ahmad, University of Colorado, Denver, United States of America
Received January 24, 2014; Accepted May 23, 2014; Published June 17, 2014
Copyright:  2014 Pousada et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the grants IN-202-05 from SOGAPAR, CO-0085-10 from Actelion Pharmaceuticals and INBIOMED 2009-063 Xunta de
Galicia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors confirm that they received funding from a commercial source: ‘‘Actelion Pharmaceuticals’’. But, this does not alter their
adherence to PLOS ONE policies on sharing data and materials.
* E-mail: dianaval@uvigo.es
Introduction
Pulmonary arterial hypertension (PAH; OMIM #178600) is a
rare and progressive disorder characterized by obstruction of pre-
capillary pulmonary arteries [1]. It is defined by a sustained
increase in mean pulmonary artery pressure (mPaP) $25 mmHg
at rest with normal wedge pressure [2]. Symptoms of PAH include
dyspnea, syncope and chest pain, and eventually leads to right-
sided heart failure and death [1]. Structural and functional
changes in the vascular wall and thrombus formation are the main
factors responsible for the increased pulmonary vascular resistance
in these patients [3].
PAH can be inherited (FPAH), idiopathic (IPAH), or associated
with other diseases, drug or toxin exposures (APAH) [4]. The
disease is more frequent in women, with a ratio of at least 1.7:1
women to men [2]. Much of what is known about the genetic basis
of PAH is related to mutations in bone morphogenetic protein
receptor type 2 (BMPR2). This gene is located on chromosome
2q33 and mutations have been identified in over 80% of patients
with FPAH, but are likely to be responsible for over 90% of the
cases. However, only 20% of carriers developed the disease [5,6].
The frequency of mutations in BMPR2 gene is not well defined in
IPAH, but it has been reported a value of 9–26% in small cohorts
of patients [6,7,8].
Some other genes have been implicated in the pathogenesis of
the disease, including Activin A type II receptor like kinase 1
(ALK1/ACVRL1) and potassium voltage-gated channel, shakerre-
lated subfamily, member 5 (KCNA5). Mutations in ACVRL1 gene,
located in chromosome 12q13, are directly related to some cases of
PAH associated with hereditary hemorrhagic telangiectasia (HHT)
[9]. This receptor is also a member of the transforming growth
factor beta (TGF-b) superfamily and plays a role in different tissues
producing different responses, including proliferation, differentia-
tion, migration, increase of cell survival and angiogenesis. ACVRL1
is expressed mainly in the developing vascular system and plays a
critical role in arteriogenesis and developing arterial endothelial
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cells [10,11]. KCNA5 protein is situated in the cellular intermem-
brane space and is composed by four subunits. The KCNA5 gene is
located on chromosome 12p13 and is formed by a single exon of
2865 bp and 613 residues. Indeed, mutations in the exon or in the
promoter region of KCNA5 gene have been reported to be
associated with IPAH and may underline the altered function and
expression of voltage-gated K+ channel 1.5 (Kv1.5) observed in
pulmonary arteriolar smooth muscle cells (PASMC) from these
patients [12,13].
The aim of this study was to analyze BMPR2, ACVRL1 and
KCNA5 genes in patients with idiopathic and associated PAH,




Patients with idiopathic or associated PAH (group 1 of Dana
Point) followed in our clinic of PAH were included in this study.
Cardiac catheterization was performed using the latest consensus
diagnostic criteria of the ERS-ESC (European Respiratory
Society-European Society of Cardiology) (mean resting pulmonary
pressure $25 mmHg, capillary pressure ,15 mmHg) in all cases,
[14]. PAH was considered idiopathic after exclusion of any of the
possible causes associated with the disease. Clinical history
included use of drugs, especially appetite suppressants, and
screening for connective tissue diseases and hepatic disease. The
study included serology for HIV, autoimmunity, thoracic CT scan
and echocardiography. Patients with PAH that could be related to
chronic lung disease were excluded. Fifty healthy individuals were
used as controls. All patients and controls signed an informed
consent. The Autonomic Ethics Committee approved the study
(Comité Autonómico de Ética da Investigación de Galicia - CAEI de Galicia).
Genomic DNA was extracted from leukocytes isolated from
venous blood using the FlexiGene DNA Kit (Qiagen, Germany)
according to the manufacturer’s protocol.
Genomic study
Amplification of the exons and intronic junctions of the genes
was performed with 50 ng of genomic DNA from each individual.
Changes in other regions were not analyzed. The primers used for
the BMPR2 gene were as described by Deng et al [15]. The
amplification conditions were as follows: 95uC for 5 min, 35 cycles
of 95uC for 30 s, 55uC for 30 s (for the exons 1, 3, 5, 6, 7, 8, 9, 10,
11 and 13) and 60uC for 30 s (for the exons 2 and 12), 72uC for
30 s and, finally, 72uC for 7 min. The PCR mix contained
1.5 mM Cl2 Mg, with 0.2 U of Taq Polymerase (Biotaq, Bioline,
UK).
The exons and intronic junctions of the ACVRL1 gene were
amplified using the conditions of 95uC for 1 min followed by 35
cycles of 95uC for 30 s, 55uC for 30 s (for the exons 5, 7, 8, 9 and
10), 56uC for 30 s (for the exon 4), 60uC for 30 s (for the exon 6),
62uC for 30 s (for the exon 2) and 64uC for the exon 3), 72uC for
30 s and, finally, 72uC for 7 min. The primers used to amplify this
gene were described by Berg et al [16].
The single exon and intronic junctions of the KCNA5 gene was
amplified for the 4 validated amplicons spanning the coding
sequence of KCNA5 gene. The primers used were described by
Tao Yang et al [17]. The amplification conditions were 95uC for
30 s, followed by 35 cycles of 95uC for 30 s, 66uC for 30 s, 72uC
for 30 s and, finally, 72uC for 7 min.
PCR products were confirmed by electrophoresis on a 2%
agarose gel containing ethidium bromide. PCR fragments were
purified using the Nucleic Acid and Protein Purification kit
(NucleoSpin Extract II; Macherey-Nagel, Germany) and se-
quenced with the BigDye Terminator version 1.1 Cycle Sequenc-
ing Kit (Applied Biosystems, California, USA). The reactions were
performed on a GeneAmp PCR System 2700 (Applied Biosys-
tems). The sequencing reactions were precipitated and finally
analyzed on an ABI PRISM 3100 genetic analyzer (Applied
Biosystems).
Sequence data was aligned to reference Ensembl cDNA
sequence ENST00000374580 for BMPR2 gene,
ENST00000388922 for ACVRL1 gene and ENST00000252321
for the KCNA5 gene and examined for sequence variations.
Detected mutations were confirmed by a second independent
PCR reaction and were identified in both forward and reverse
strands. To predict whether a rare missense variant was
deleterious, we used the combined results of three different
computer algorithms:
– The polymorphism phenotyping program, PolyPhen-2 (avail-
able at http://genetics.bwh.harvard.edu/pph/) uses sequence
conservation, structure and SWISS-PROT annotation to
characterize an amino acid substitution as benign, possibly
damaging or probably damaging [18].
– Pmut (available at http://mmb2.pcb.ub.es:8080/PMut/) pro-
vides prediction by neural networks, which use internal
databases, secondary structure prediction and sequence
conservation. This program provides a binary prediction of
‘‘neutral’’ or ‘‘pathologic’’ [19].
– Sort Intolerant from Tolerant (SIFT) (available at http://sift.
jcvi.org) uses sequence homology to predict whether a change
is tolerated or damaging [20].
Intronic, isocoding and missense changes were analyzed using
the programs NNSplice (http://fruitfly.org:9005/seq_tools/splice.
html), NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/),
Splice View (http://zeus2.itb.cnr.it/,webgene/wwwspliceview_ex.
html) and HSF Human (http://www.umd.be/HSF/) in order to
predict whether those changes could be affecting, creating or
eliminating donor/acceptor splice sites.
Statistical analysis
Values are expressed as mean6SD (standard deviation). A non-
parametric test was used for comparisons between patients and
controls. Chi-square test was used to compare genotype with
clinical and hemodynamic variables. These correlations were
analyzed by the Spearman test. Values ,0.05 were considered
statistically significant. Analysis was carried out using the statistical
package SPSS v19.
Results
Description of the cohort
Forty one unrelated PAH patients (16 idiopathic, 17 associated
to connective tissue disease, 4 related to HIV and 4 porto-
pulmonary) and fifty healthy controls without familial history of
PAH were included. At the time of diagnosis 3 patients were in
functional class (FC) I, 14 patients in FC II, 21 patients in FC III
and 3 in FC IV. The clinical features of patients are showed in
Table 1.
Mutations in BMPR2, ACVRL1 and KCNA5 genes
A total of 53 nucleotide changes in the BMPR2, ACVRL1 and
KCNA5 genes were identified in 40 out of 41 patients. We found 30
changes in 33 patients in BMPR2 gene, 11 variations in 24 patients
Mutations in Related Genes in PAH
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in ACVRL1 gene, and 12 changes in 15 patients in the case of
KCNA5 gene.
Thirty-one variations (60.8%) were located in coding regions.
Missense variations accounted for 39.6% of total changes found in
coding regions; nonsense variations only represented 5.7% and
synonymous changes a 13%. The 26.4% of changes were located
in intronic regions (two of them were heterozygous deletions) and a
9.4% in UTR regions of these genes. (Figure 1).
The three different computer algorithms used to classify the
nucleotide changes showed different results. A missense mutation
was considered pathogenic when at least two of the three programs
(PolyPhen-2, Pmut and SIFT) classified it as pathogenic. These
changes are summarized in Table 2. None of these mutations were
detected in a panel of 100 chromosomes from controls.
Furthermore, we used four programs to predict whether these
changes could affect donor/acceptor splice sites. We consider a
mutation as potentially pathogenic when the pathogenic score was
equal or greater than 2 (Tables 3, 4, 5).
After the combination of all software, we found 22 pathological
mutations in 21 patients, with a frequency of 51%. Most of the
mutations were found in BMPR2 gene (41.5%), followed by
KCNA5 (7.3%) and, finally, ACVRL1 (4.9%). These results are
shown in Figure 2. IPAH patients were carriers of BMPR2
mutations in 8 cases (50%), two cases for KCNA5 gene (12.5%) and
2 cases for ACVRL1 gene (12.5%) (Figure 2). The 62.5% of patients
(10patients) with IPAH had at least one pathogenic mutation in
some of these genes. On the other hand, 44% (11 patients) of
APAH patients showed pathogenic mutations (36% in BMPR2
gene, 4% in ACVRL1 gene and 4% in KCNA5 gene).
In our cohort of patients we found 5 patients with more than
one pathogenic mutation in BMPR2 or in combination with
KCNA5 or ACVRL1 genes (Table 6). All of these mutations are
described for first time in this study, except c.529+37C.G.
Association with clinical features and hemodynamic
parameters
We analyzed clinical features and hemodynamic parameters
comparing the group of patients harboring a pathogenic mutation
with those patients with no mutation. The parameters included
were: gender, age at diagnosis, mPaP (mean pulmonary pressure),
Table 1. Clinical features and hemodynamic parameters of patients.
Carriers of mutations Non-carriers of mutations p-value Idiopathic PAH Associated PAH p-value
Number 20 21 16 25
Gender 10 F/10 M 10 F/11 M 0.216 8 F/8 M 13 F/12 M 0.552
Age at diagnosis (years) 53615 51616 0.437 52621 53612 0.552
mPaP (mmHg) 57615 45614 0.043 52616 47613 0.510
sPaP (mmHg) 69622 73619 0.448 74620 70621 0.490
PVR (mmHg.l21.m21) 11.9263.18 8.5364.46 0.043 9.9664.68 7.2162.8 0.222
CI (l.m21.m22) 2.0560.68 3.7560.44 0.040 2.660.74 2.5460.45 0.346
6MWT (m) 3146130 4286103 0.020 3706136 3746127 0.308
PAH types 10 IPAH/10 APAH 6 IPAH/15 APAH 0,222 16 patients 25 patients 0,222
Values are expressed as mean 6 standard deviation; F: female, M: male; mPaP: mean pulmonary artery pressure; sPaP: systolic pulmonary artery pressure; PVR:
pulmonary vascular resistence; CI: cardiac index; 6MWT: 6 minute walking test; IPAH: idiopathic pulmonary arterial hypertension; APAH: associated pulmonary arterial
hypertension.
doi:10.1371/journal.pone.0100261.t001
Figure 1. Total percentage of nucleotide changes found in this study for the analyzed genes. The variations that appear in greater
proportion are missense, followed by those located in the intronic region.
doi:10.1371/journal.pone.0100261.g001
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Table 3. Results from four different bioinformatic programs used to predict the effect on the splicing process in BMPR2 gene
(NNSplice, NetGene2, Splice View and HSF Human).
Sequence variants NNSplice NetGene2 Splice View HSF Human Score
c.1-301G.A The WT consensus
sequence
is not recognized
Score for the aceptor site





c.190A.C (p.(S64G)) Neutral The WT consensus sequence
is not recognized
A new donor site
is created
Score for donor and
acceptor site decreases
2
c.229A.T (p.(I77L)) The WT consensus
sequence
is not recognized
Score for the main donor site
increases from 31 to 34
Neutral A new acceptor site
is created
2
c.251G.T (p.(C84F)) Score for the aceptor site
increases from 87 to 89
Score for the main acceptor site
decreases from 33 to 27
Neutral The main donor site
is not recognized
3
c.259C.T (p.(H87Y)) Score for the aceptor site
decreases from 87 to 86
Score for the main acceptor site
decreases from 33 to 30




c.275A.T (p.(Q92L)) Neutral Score for the main acceptor site
decreases from 33 to 25
Neutral Score for donor and acceptor
site increases
2
c.327G.C (p.(Q109Q)) Neutral Score for the main donor site
decreases from 79 to 76
Neutral The main donor site is
not recognized
2
c.419-43delT Neutral Neutral Neutral Neutral 0
c.484G.C (p.(A162P)) Score for the aceptor site
decreases from 80 to 66
Neutral Neutral The main donor site is not
recognized
2
c.529+37C.G A new acceptor site
is created
Neutral Neutral A new acceptor site is created 2
c.529+53A.G Neutral Neutral Neutral A new acceptor site is created 1
c.529+139A.T Neutral Neutral Neutral Score for donor site decreases
and the acceptor site increase
1
c.530-24G.T Neutral Score for the main donor site
increases from 83 to 86 and the
main acceptor site increases
from 77 to 82
Neutral The donor and acceptor sites
is not recognized
2
c.622+103C.G Neutral Neutral Neutral The main donor site is not
recognized
1
c.633A.G (p.(R211R)) Neutral Score for the main donor site
increases from 92 to 94
Neutral The main donor site is not
recognized and the acceptor
decrease
2
c.637C.A (p.(R213R)) Neutral Score for the main acceptor site
decreases from 20 to 18
Neutral Score for donor site increases
and a new acceptor site is created
2
c.654T.A (p.(Y218*)) Neutral Score for the main donor site
increases from 92 to 94 and
the main acceptor site
decreases from 20 to 18
Neutral Score for the main acceptor
site decrease
2
c.790G.A (p.(D264N)) Neutral Score for the main donor site
decreases from 94 to 92
Neutral The main donor site is not
recognized
2
c.835G.T (p.(V278V)) Neutral Neutral Neutral Score for donor site decreases
and the acceptor site increase
1
c.853-22T.C Neutral Score for the main donor site
decreases from 87 to 86
Neutral Neutral 1
c.968+117G.A BMPR2 Neutral Neutral Neutral The donor and acceptor sites
is not recognized
1
c.968-124_968-122delTCT Neutral Neutral Neutral Neutral 0





The main donor site increase and
a new acceptor site in created
2
c.981T.C (p.(P327P)) The WT consensus
sequence
is not recognized
Score for the main donor site
decreases from 100 to 99
Neutral A new donor site is created 2
c.1021G.A (p.(V341M)) Neutral Neutral The WT consensus
sequence is
not recognized
The main donor site is not
recognized
2
c.1414-84C.T Neutral Neutral Neutral Score for the main acceptor site
increases
1
Mutations in Related Genes in PAH
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sPaP (systolic pulmonary pressure), PVR (pulmonary vascular
resistence), CI (cardiac index), 6MWT (6 minute walking test) and
type of PAH (IPAH vs APAH). Variables were categorized
according to the best cut off point by ROC curve.
The association of genotype with clinical and hemodynamics
parameters showed statistically significant differences in mPaP
(p = 0.043) and PVR (p = 0.043). Patients carrying a mutation had
a higher value for these two parameters than non-carriers. In
opposition, patients carrying a mutation had a significantly lower
CI (p = 0.04) and 6MWT (p = 0.02). These results are shown in
table 1. We did not found significant differences between gender
for the presence of mutations (p = 0.216), mean age of onset of first
symptoms (p = 0.437) and sPaP (p = 0.448). Pathological mutations
were seen in 10 patients with IPAH and 10 patients with
associated PAH without statistical differences (p = 0,222). Clinical
and hemodynamic parameters did not show any significant
difference between associated and idiopathic PAH.
The mean follow-up period was 14 months. Three patients died
during this time (2 APAH, 1 IPAH), so it was not possible to
compare groups. Two of the three deceased patients present two
pathogenic mutations in BMPR2 gene. The other patient was
carrier of a pathogenic mutation, (p.(A162P)) in BMPR2 gene and
showed several polymorphisms in ACVRL1 (c.1047+31C.A,
c.1186A.G (p.(T396A)), c.1502+7A.G) and KCNA5 (c.1842+
508A.T) genes.
Table 3. Cont.
Sequence variants NNSplice NetGene2 Splice View HSF Human Score
c.1467G.A (p.(E489E)) Neutral Score for the main donor site
increases from 89 to 93
Neutral A new acceptor site is created 2
c.2034G.A (p.(K678K)) Neutral Neutral Neutral The main donor site is not
recognized
1
c.2324G.A (p.(S775N)) Neutral Neutral Neutral The main donor site is not
recognized
1
c.2811G.A (p.(R937R)) Neutral Neutral Neutral The main donor site is not
recognized
1
These results are considered positive if the score is equal or greater than two.
doi:10.1371/journal.pone.0100261.t003
Table 4. Results from four different bioinformatic programs used to predict the effect on the splicing process in ACVRL1 gene
(NNSplice, NetGene2, Splice View and HSF Human).
Sequence variants NNSplice NetGene2 Splice View HSF Human Score
c.24A.T (p.(K8N)) Score for the main
acceptor site increases
from 66 to 76
Neutral Neutral The main donor and acceptor sites
are not recognized
2
c.176A.T (p.(E59V)) Neutral Neutral Neutral The main donor site is not recognized
and a new acceptor site is created
0
c.313+11C.T Neutral Neutral Neutral Score for acceptor site decreases 1
c.313+20C.A Neutral Neutral Neutral Score for acceptor site increase 1






Neutral The main donor site is not recognized
and acceptor site increase
0
c.478delT (p.(S160Pfs*5)) Neutral Neutral Neutral The main donor site is not recognized 1
c.673A.T (p.(S225C)) Score for the main donor
site
increases from 95 to 99
Score for the main donor
site




The main donor site is not recognized
and a new acceptor site is created
2






Neutral The main donor site is not recognized 1
c.1186A.G (p.(T396A)) The WT consensus
sequence
is not recognized
Neutral Neutral Score for the main donor site increases 0
c.1246+41G.C The WT consensus
sequence
is not recognized
Neutral Neutral The main acceptor site is not recognized 0
c.1502+7A.G Neutral Score for the main donor
site





These results are considered positive if the score is equal or greater than two.
doi:10.1371/journal.pone.0100261.t004
Mutations in Related Genes in PAH
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Discussion
This study was designed to establish the prevalence of mutations
found in certain genes potentially involved in the pathogenesis of
PAH. We detected 53 different nucleotide changes in BMPR2,
ACVRL1 and KCNA5 genes in 40 out of 41 PAH patients. Twenty
two of these mutations (found in 51% of patients) were considered
pathogenic according to the in silico analysis that was performed
with several programs to reach a high reliability [21].
The mutational frequency for BMPR2 gene in sporadic PAH
range from 10–20%, as referred in previous studies
[22,23,24].However, we found that 50% of our IPAH patients
had a pathogenic mutation in BMPR2 gene,higher than expected
and corresponding to the highest value described until now. The
percentage of mutations found in APAH was 36%, which is lower
but also significantly elevated. Consider the suggestion made by
Pfarr et al [25] that as soon a genetic defect had been identified in
PAH patients they must be classified as familial PAH, it could be
interesting to perform segregation analysis in order to confirm the
familial nature of the disease in these families.
We identified two hot spots for mutations in exon 3 and exon
6 for BMPR2 gene. These exons are located in a very important
area rich in cysteine residues and therefore any mutation here
could affect the catalytic ability of the BMPs, the ligand of BMPR2,
disrupting the Smad signaling pathway [2,23,26,27,28]. These
mutations may introduce subtle changes in the structure of the
protein and might interfere with the downstream signaling of the
BMP pathway [29]. It has been hypothesized that an imbalance of
increased TGF-b levels and decreased BMP signals induced by
BMPR2 mutations leads to PAH [30]. Exon 6 is located in the N-
terminus of a serine-threonine kinase domain which is formed by
conserved subdomains that includes exons 6 to 11 of the gene.
This region, responsible for binding adenosine triphosphate (ATP),
is characterized by distinctive patterns of conserved residues.
Mutations located here could produce heterogeneous defects for
signaling activity by binding preventing of ATP and altering the
functionality of the protein. We also detected several mutations in
the C-terminus region for this serine-threonine kinase domain,
which is involved in substrate recognition and initiation of the
phosphorylation relay. In addition, one missense mutation and one
synonymous change, which seems to alter the splicing process
Table 5. Results from four different bioinformatic programs used to predict the effect on the splicing process in KCNA5 gene
(NNSplice, NetGene2, Splice View and HSF Human).
Sequence variants NNSplice NetGene2 Splice View HSF Human Score
c.125T.A (p.(L42H)) The WT consensus
sequence
is not recognized





The WT consensus sequence
is not recognized
0
c.253C.A (p.(L85M)) The WT consensus
sequence
is not recognized





The WT consensus sequence
is not recognized
0
c.340A.C (p.(T114P)) The WT consensus
sequence
is not recognized





The WT consensus sequence
is not recognized
0
c.385C.G (p.(L119V)) The WT consensus
sequence
is not recognized






c.477G.C (p.(L159L)) The WT consensus
sequence
is not recognized





Score for the main acceptor
site increase
1
c.509C.G (p.(P170R)) The WT consensus
sequence
is not recognized





The WT consensus sequence
is not recognized
0
c.551G.C (p.(R184P)) The WT consensus
sequence
is not recognized





The WT consensus sequence
is not recognized
0
c.622G.T (p.(E208*)) The WT consensus
sequence
is not recognized





The main donor site is not
recognized and acceptor site
increase
1
c.1733G.A (p.(R577K)) The WT consensus
sequence
is not recognized





The WT consensus sequence
is not recognized
0
c.1842+22T.G The WT consensus
sequence
is not recognized





The WT consensus sequence
is not recognized
0
c.1842+52A.T The WT consensus
sequence
is not recognized





The WT consensus sequence
is not recognized
0
c.1842+508A.T The WT consensus
sequence
is not recognized





The WT consensus sequence
is not recognized
0
These results are considered positive if the score is equal or greater than two.
doi:10.1371/journal.pone.0100261.t005
Mutations in Related Genes in PAH
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according to in silico analysis, were identified in exon 8.Finally, we
found the synonymous mutation p.(E489E) in exon 11, which is
predicted to produce alterations at splicing level. An invariant
arginine at position 491 in the protein is located around this point,
which is essential for signaling [31], thereby making this area of
special interest.
Synonymous mutations have always been considered safe, but
they could cause serious physiological effects as they can interfere
in the splicing accuracy, translation fidelity, mRNA structure and
protein folding. Even, these mutations may decrease the half-life of
mRNA, leading to a downregulation of the protein expression
[32]. Different synonymous mutations, both new and already
described, were seen in 46% of our patients and the 62.5% of these
synonymous mutations are considered pathogenic and were not
found in controls. It could be interesting to analyze synonymous
mutations and intronic deletions [23] with a functional approach
since no studies have been performed for these changes.
Regarding to the ACVRL1 gene, several mutations have usually
been described associated with HHT. Girerd et al describe a
mutational frequency for this gene of 2.3% in IPAH patients from
the French PAH Network, lower than 12.5% found in our patients
[33]. Probably the small size of our series may explain these
differences. When we compared the data for IPAH in this paper
against our results, we found a higher mutational rate for BMPR2
and ACVRL1 genes (59% vs 16.6%), finding only one mutation
(p.(S160P)fs*5) in ACVRL1 in one APAH patient. Selva-O’Call-
aghan et al, who studied mutational load for ACVRL1 gene in
APAH to connective tissue disease patients [34], did not found any
mutation. These findings suggest that ACVRL1 gene do not have a
significant role in APAH patients.
The p.(S225C) mutation is located in exon 6 of ACVRL1 gene
and it is placed in the serine-threonine kinase domain. Mutations
in this region, a conserved serine–threonine kinase domain, have
been associated with a higher risk of PAH in childhood and could
affect the downstream SMAD signaling pathway as BMPR2
[35,36]. The novel missense mutation, p.(T396A) was detected in
8 patients and does not appear in the control group. Functional
studies from Abdalla et al [36] demonstrated that mutations
located in this highly conserved protein domain may cause protein
misfolding [36,37] and intracellular degradation, explaining the
lack of surface expression of mutant proteins [36]. Although it has
been classified as nonpathogenic, it would be interesting to
determine its functionality.
Few mutations have been described in highly conserved
aminoacid residues of the KCNA5 gene in PAH patients [38].
Several KCNA5 gene mutations have been involved in atrial
fibrillation, a common cardiac arrhythmia, in 1.95% of patients
with absence of known predisposing factors [39]. We detect
pathological mutations in this gene in 7.3% of total patients. For
IPAH patients this value raises to 12.5%, but only one mutation
was identified in one APAH patient.
Figure 2. Frequency of pathological mutations found in our patients (blue all patients, yellow IPAH, purple APAH). BMPR2 showed
the greatest number of mutations.
doi:10.1371/journal.pone.0100261.g002
Table 6. List of patients with several pathogenic mutations in the studied genes.
Patient BMPR2 ACVRL1 KCNA5 PAH Type
14.09 c.251G.T (p.(C84F)), c.259C.T (p.(H87Y))a, c.981T.C (p.(P327P)) a – – Associated
14.17 c.530+37C.G a – c.551G.C (p.(R184P)) Idiopathic
17.01 c.893G.A (p.(W298*)) c.24A.T (p.(K8N)) a – Idiopathic
PO.15 c.229A.T (p.(I77L))a, c.633A.G (p.(R211R)) a – – Idiopathic
PO.16 c.327G.C (p.(Q109Q)) a, c.1021G.A (p.(V341M)) – – Associated
aThese mutationsare considered pathogenic because they could produce alterations in the splicing process, according to in silico analysis.
doi:10.1371/journal.pone.0100261.t006
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The p.(P170R), p.(R184P) and p.(E208*) mutations in KCNA5
gene are located within the T1 domain, which is highly conserved.
The T1 domain is largely responsible for tetramerization and
governs channel interaction by cytoplasmic regulatory subunits
KVa and KVb. Mutations located in this region have been shown
to disrupt both KVa-KVb with deleterious consequences on
channel gating, protein expression [40] or cause both hyperpo-
larizing and depolarizing shifts on the activation relationship
[41,42]. T1 domain has also been associated with other aspects of
channel function as the interaction with S1 domain or the
influence in gating properties and voltage sensitivity of KV
channels. Furthermore, the p.(E208*) mutation is close to S1
domain and potentially can disrupt the creating side portals
between the T1 domain and the pore. Even mutations that have
been identify as no harmful for the protein and did not appear in
controls, as p.(L42H), p.(T114P) and p.(R577K) could introduce
subtle changes in the structure of the protein and might interfere
with the proper operation of the Kv1.5 channels, since they are
located between the 59UTR region of the gene and heteromeriza-
tion domain, where the association between different proteins
occurs [38].
We found statistical differences for mPaP, PVR, CI and 6MWT
when compared hemodynamics and clinical parameters between
patients with and without pathogenic mutations. Patients who
harbor mutations show higher values for mPaP and PVR.
Conversely, values for CI and 6MWT were significantly smaller.
These results seem to show that patients with mutations have a
more severe disease and perhaps worse prognosis. Otherwise,Pfarr
et al found significant differences only for a low PVR value [25].
On the other hand, no differences in these parameters were seen
according to PAH type. Liu D et al have described that gender
influences the phenotype in PAH patients with BMPR2 mutations,
being more severe in males, but we did not confirm this fact in our
results [43]. Previous studies indicate that PAH patients carrying a
mutation have an onset approximately 10 years earlier than non-
carriers [31], but our results did not confirm this finding. The vast
majority of these variations are private, so it makes very difficult to
establish a correlation between the phenotype and one particular
mutation. For this reason, genotype-phenotype correlation is made
according to all mutations found in a group of patients.
We described for the first time 5 patients with multiple
mutations, three of them with two or more mutations in BMPR2
gene. Two patients, both with IPAH, were carriers of mutations in
two genes, BMPR2 and KCNA5 genes in one case and BMPR2 and
ACVRL1 genes in the other one. This genetic heterogeneity
reinforces the complex pathogenicity of this disease, with several
ways of actuation. The molecular mechanisms of PAH are not
clearly understood but multiple factors are involved in the
development of this disease and several genes could be mutated,
so it is not surprising that one patient may require mutations in
several genes to develop PAH. The small number of patients with
various mutations does not allow comparisons, but 3 of these 5
patients had a younger age at diagnosis and 2 of them died during
follow-up which may suggest a worse prognosis.
Obviously, the main limitation of our study is the small number
of patients, although the low incidence of PAH and some cases
that did not consent the inclusion in this study, did not allow us to
have a larger series. The comprehensive study carried out and
complete follow-up of all cases add value to our results.
In summary, we present a series of patients with idiopathic and
associated PAH with a high percentage of mutations in BMPR2
and lower in ACVRL1 and KCNA5 genes, some of them not
previously described, showing some clinical and hemodynamic
differences which suggest that the presence of these mutations may
be associated with more severe disease. There is no doubt that
other genes are involved in the pathogenesis of PAH and will be
important to know the role they play in the development of this
disease. Perhaps the presence of more than one mutation increases
the risk of develop it. As in other pathologies with genetic basis,
PAH may be caused by a total mutational load of the genes
involved in. This genetic heterogeneity, when known, may allow
us to establish a correlation with the severity and course of the
disease. The more we known about the pathways involved the best
we can design the treatment.
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BMPR2 gene in patients with pulmonary arterial hypertension. Arch
Bronconeumol 46: 129–34.
23. Fessel JP, Loyd JE, Austin ED (2011) The genetics of pulmonary arterial
hypertension in the post-BMPR2 era. Pulm Circ 1: 305–319.
24. Girerd B, Montani D, Eyries M, Yaici A, Sztrymf B, et al. (2010) Absence of
influence of gender and BMPR2 mutation type on clinical phenotypes of
pulmonary arterial hypertension. Respir Res 11: 73–80.
25. Pfarr N, Fischer C, Ehlken N, Becker-Grünig T, López-González V, et al. (2013)
Hemodynamic and genetic analysis in children with idiopathic, heritable, and
congenital heart disease associated pulmonary arterial hypertension. Respir Res
14: 3–12.
26. Elliot CG, Glissmeyer EW, Havlena GT, Carlquist J, McKinney JT, et al. (2006)
Relationship of BMPR2 mutations to vasoreactivity in Pulmonary Arterial
Hypertension. Circulation 113: 2509–2515.
27. Hamid R, Cogan JD, Hedges LK, Austin E, Phillips III JA, et al. (2009)
Penetrance of Pulmonary Arterial Hypertension is modulated by the expression
of normal BMPR2 allele. Hum Mutat 30(4): 649–654.
28. Majka S, Hagen M, Blackwell T, Harral J, Johnson JA, et al. (2011) Physiologic
and molecular consequences of endothelial BMPR2 mutation. Respir Res 12:
84–96.
29. Pfarr N, Szamalek-Hoegel J, Fischer C, Hinderhofer K, Nagel C, et al. (2011)
Hemodynamic and clinical onset in patients with hereditary pulmonary arterial
hypertension and BMPR2 mutations. Respir Res 12: 99–109.
30. Chida A, Shintani M, Nakayama T, Furutani Y, Hayama E, et al. (2012)
Missense Mutations of the BMPR1B (ALK6) Gene in Childhood Idiopathic
Pulmonary Arterial Hypertension. Circ J 76(7): 1804–1811.
31. Machado RD, Aldred MA, James V, Harrison RE, Patel B, et al. (2006)
Mutations of the TGF-b Type II Receptor BMPR2 in Pulmonary Arterial
Hypertension. Hum Mutat 27(2): 121–132.
32. Czech A, Fedyunin I, Zhang G, Ignatova Z (2010) Silent mutations in sight: co-
variations in tRNA abundance as a key to unravel consequences of silent
mutations. Mol BioSyst 6: 1767–1772.
33. Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, et al. (2010) Clinical
Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an
ACVRL1 (ALK1) Mutation. Am J Respir Crit Care Med 181: 851–861.
34. Selva-O’Callaghan A, Balada E, Serrano-Acedo S, Simeon-Aznar CP, Ordi-Ros
J (2007) Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in
patients with pulmonary hypertension and underlying connective tissue disease.
Clin Rheumatol 26: 947–949.
35. Fujiwara M, Yagi H, Matsuoka R, Akimoto K, Furutani M, et al. (2008)
Implications of Mutations of Activin Receptor-Like Kinase 1 Gene (ALK1) in
Addition to Bone Morphogenetic Protein Receptor II Gene (BMPR2) in
Children With Pulmonary Arterial Hypertension. Circ J 72: 127–133.
36. Abdalla SA, Cymerman U, Johnson RM, Deber CM, Letarte M (2003) Disease-
associated mutations in conserved residues of ALK-1 kinase domain. Eur J Hum
Genet 11: 279–287.
37. Schulte C, Geisthoff U, Lux A, Kupkal S, Zenner HP, et al. (2005) High
frequency of ENG and ALK1/ACVRL1 mutations in german HHT patients.
Hum Mutat 25(6): 595–602.
38. Remillard CV, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, et al. (2007)
Function of Kv1.5 channels and genetic variations of KCNA5 in patients with
idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol 292:
C1837–C1853.
39. Christophersen IE, Olesen MS, Liang B, Andersen MN, Larsen AP, et al. (2013)
Genetic variation in KCNA5: impact on the atrial-specific potassium current
IKur in patients with lone atrial fibrillation. Eur Heart J 34(20): 1517–25.
40. Burg ED, Platoshyn O, Tsigelny IF, Lozano-Ruiz B, Rana BK, et al. (2010)
Tetramerization domain mutations in KCNA5 affect channel kinetics and cause
abnormal trafficking patterns. Am J Physiol Cell Physiol 98(3): C496–509.
41. Kurata HT, Soon GS, Eldstrom JR, Lu GW, Steele DF, et al. (2002) Amino-
terminal determinants of U-type inactivation of voltage-gated K+ channels. J Biol
Chem 277(32): 29045–53.
42. Park WS, Firth AL, Han J, Ko EA (2010) Patho-, physiological roles of voltage-
dependent K+ channels in pulmonary arterial smooth muscle cells. J. Smooth
Muscle Res 46(2): 89–105.
43. Liu D, Wu WH, Mao YM, Yuan P, Zhang R, et al. (2012) BMPR2 mutations
influence phenotype more obviously in male patients with pulmonary arterial
hypertension. Circ Cardiovasc Genet 5(5): 511–8.
Mutations in Related Genes in PAH
PLOS ONE | www.plosone.org 10 June 2014 | Volume 9 | Issue 6 | e100261
